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Background. Growing evidence highlights the relevance of posterior cortically-based cognitive deficits in 
Parkinson’s disease (PD) as possible biomarkers of the evolution to dementia. Cross-sectional correlational 
studies have established a relationship between the degree of atrophy in posterior brain regions and 
visuospatial and visuoperceptual (VS/VP) impairment. The aim of this study is to address the progressive 
cortical thinning correlates of VS/VP performance in PD.  
Methods. Forty-four PD patients and 20 matched healthy subjects were included in this study and followed for 
4 years. Tests used to assess VS/VP functions included were: Benton’s Judgement of Line Orientation (JLOT), 
Facial Recognition (FRT), and Visual Form Discrimination (VFDT) Tests; Symbol Digit Modalities Test (SDMT); 
and the Pentagon Copying Test (PCT). Structural magnetic resonance imaging data and FreeSurfer were used 
to evaluate cortical thinning evolution.  
Results. PD patients with normal cognition (PD-NC) and PD patients with mild cognitive impairment (PD-MCI) 
differed significantly in the progression of cortical thinning in posterior regions. In PD-MCI patients, the 
change in VS/VP functions assessed by PCT, JLOT, FRT, and SMDT correlated with the symmetrized percent 
change of cortical thinning of occipital, parietal, and temporal regions. In PD-NC patients, we also observed a 
correlation between changes in FRT and thinning in parieto-occipital regions. 
Conclusion. In this study, we establish the neuroanatomical substrate of progressive changes in VS/VP 
performance in PD patients with and without MCI. In agreement with cross-sectional data, VS/VP changes 





Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder that manifests with a wide range of 
nonmotor symptoms. Recent initiatives have aimed to depict the features and evolution of cognitive decline 
in PD [1-4]. 
Impairment in specific cognitive domains has been associated with a differential risk of cognitive decline. 
While executive functions are widely recognized to be impaired in PD even at early disease stages [1,5,6], 
interest in the role of posterior cortically-based functions as biomarkers of the cognitive evolution to 
dementia (PDD) has increased [1,7,8]. 
Several cross-sectional structural MRI correlational studies have established a relationship between the 
degeneration of posterior brain regions and cognitive impairment [9-12]. Specifically, previous studies by our 
group showed that visuospatial and visuoperceptual (VS/VP) tests are suitable to reflect cortical thinning in 
lateral temporo-parietal regions in PD patients [13,14]. 
Longitudinal studies have assessed structural gray matter differences over time in PD [15,16], and the 
progression of cognitive impairment has been related to degeneration of several cortical regions, including 
bilateral frontal and temporoparietal areas [16-18]. Progressive atrophy in widespread brain regions, such as 
the bilateral temporal and right occipital medial lobes, left superior frontal gyrus, and inferior parietal cortex, 
has been related to worsening in measures of global cognition [17,18]. Also, volumetric studies have 
associated the decline in executive functions with mainly bilateral frontal areas [19,20]. However, to the best 
of our knowledge, the relationship between the impairment of specific VS/VP functions and cortical thinning 
over time has yet to be studied. The aims of this study are (1) to address differential progressive gray matter 
loss between PD patients and healthy controls (HC), as well as (2) to investigate the changes over time in 
VS/VP functions in PD patients grouped according to cognitive status and their relationship with progressive 







The cohort of this study was recruited from an outpatient movement disorders clinic (Parkinson’s Disease and 
Movement Disorders Unit, Service of Neurology, Hospital Clínic, Barcelona, Spain), and HC were recruited 
from Institut de l’Envelliment (Barcelona, Spain). All participants are part of an ongoing longitudinal study, 
composed of 121 PD patients and 48 healthy subjects in the initial screening phase. Both groups were 
matched for age, sex, and years of education.  
Inclusion criteria for participants consisted of fulfilling the diagnostic criteria for PD established by the UK PD 
Society Brain Bank [21]. Exclusion criteria consisted of: presence of dementia according to the Movement 
Disorder Society criteria [22], Hoehn and Yahr scale (H&Y) score >3, juvenile-onset PD, presence of psychiatric 
and/or neurologic comorbidity, low global IQ score estimated by the Vocabulary subtest of the Wechsler Adult 
Intelligence Scale, 3rd edition (scalar score ≤7 points), Mini-Mental State Examination (MMSE) score ≤25, 
claustrophobia, imaging findings on MRI not compatible with PD other than mild white matter 
hyperintensities in the FLAIR sequence, and MRI artifacts. The final sample at the baseline assessment 
consisted of 92 PD patients and 36 controls. A follow-up assessment was pursued after approximately four 
years (see Table 1), with a sample of of 20 HC and 44 PD patients. Only subjects with baseline and follow-up 
assessments were included in this study (see Supplementary Figure 1).  
Motor symptoms were assessed with the Unified Parkinson’s Disease Rating Scale, motor section (UPDRS-III). 
All PD patients were taking antiparkinsonian drugs, consisting of different combinations of L-DOPA, cathecol-
O-methyltransferase inhibitors, monoamine oxidase inhibitors, dopamine agonists, and amantadine. In order 
to standardize doses, the L-DOPA equivalent daily dose (LEDD) [23] was calculated. All assessments were done 
while patients were under the effect of their usual medication (“on” state). 
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In line with the PD-MCI Movement Disorder Society Task Force (MDSTF) recommendations [24], we assessed 
five cognitive domains as previously described [12].  We divided the subjects into three groups: HC, PD 
patients without MCI (PD-NC), and PD patients with MCI (PD-MCI) at baseline. Expected z scores adjusted for 
age, sex, and education for each test and each subject were calculated based on a multiple regression analysis 
performed in the HC group [3]. As in previous studies [12,25], the presence of MCI was established if the z 
score for a given test was at least 1.5 lower than the expected score in at least two tests in one domain, or in 
at least one test per domain in at least two domains.  
Written informed consent was obtained from all study participants after full explanation of the procedures. 
The study was approved by the institutional Ethics Committee from the University of Barcelona 
(IRB00003099). 
 
Visuospatial and visuoperceptual assessment 
All participants underwent a comprehensive neuropsychological assessment with VS/VP tests usually 
employed to evaluate the cognitive status of PD patients. The battery of tests chosen in this study is the same 
as that used in a previous cross-sectional study that addressed the neuroanatomical correlates of VS/VP 
deficits in PD [14].  The tests included were the pentagon copying test (PCT) from the MMSE, scored 
according to the Modified Mini-Mental State criteria (3MS); Benton’s Judgment of Line Orientation test 
(JLOT), Visual Form Discrimination test (VFDT), and Facial Recognition test (FRT); and Symbol Digits Modalities 
test (SDMT).  
 
MRI acquisition 
Magnetic resonance images (MRI) were acquired with a 3T scanner (MAGNETOM Trio, Siemens, Germany) at 
baseline and follow-up. The scanning protocol included high-resolution 3-dimensional T1-weighted images 
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acquired in the sagittal plane (TR=2300 ms, TE=2.98ms, TI=900ms, 240 slices, FOV=256mm; matrix 




Longitudinal cortical thickness 
FreeSurfer software (version 5.1; available at http://surfer.nmr.harvard.edu) was used to obtain structural 
measures as previously described [13].  After processing each subject cross-sectionally, in order to perform 
the longitudinal analyses of the data, within-subject templates [26] and corresponding longitudinal files were 
created for each time point for each subject. Briefly, a template volume for each subject using information 
from all of their time points and an average image were created using robust, inverse, consistent registration 
[27]. All time points were constructed through unbiased mean images and later aligned. After registration and 
creation of the templates, images from all time points are mapped to the template location and averaged, 
and processed with the default cross-sectional stream. The symmetrized percent change was used for 
longitudinal analyses of cortical thickness: [(Thickness at time point 1 – Thickness at time point 2)/Interval 
between assessments)]/[0.5*(Thickness at time point 1 + Thickness at time point 2)].  
Comparisons between groups and regressions were assessed using vertex-by-vertex general linear models. 
Multiple contrasts were carried out to assess differences between all study subgroups (HC vs. all PD patients; 
HC vs. PD-NC; HC vs. PD-MCI; and PD-NC vs. PD-MCI). Regression models included symmetrized percent 
change as an independent factor and cognitive scores as dependent factors. In order to avoid clusters 
appearing significant purely by chance (i.e., false positives), Monte Carlo null-Z simulation with 10,000 
iterations was applied to cortical thickness maps to provide clusterwise correction for multiple comparisons. 




Global atrophy measures 
Gray matter and lateral ventricular volumes were obtained automatically via whole brain segmentation 
procedures performed with FreeSurfer (version 5.1; available at http://surfer.nmr.harvard.edu). Intracranial 
volume (ICV) was entered as a covariate of no interest in comparisons of global atrophy measures. Mean 
thickness for both hemispheres was calculated as follows: [(left hemisphere thickness * left hemisphere 
surface area) + (right hemisphere thickness * right hemisphere surface area)]/(left hemisphere surface area + 
right hemisphere surface area).  
 
Statistical analyses 
Statistical analyses of neuropsychological, demographic, clinical, and MRI volumetric data variables were 
carried out using the statistical package SPSS-20 (2011; Armonk, NY: IBM Corp.). For the baseline analysis of 
demographic variables, Student t tests, ANOVA, Pearson’s χ2 statistics, and Mann-Whitney’s U were used as 
appropriate.  
A longitudinal variable was created for each test used to pair neuropsychological data with the structural 
longitudinal measure of symmetrized percent change, and was used in all statistical and structural analyses of 
the study. 
For longitudinal clinical, neuropsychological, and structural variables, repeated measures general linear model 
was used to assess group differences over time in quantitative variables; and post-hoc tests were performed 
using Bonferroni correction for multiple comparisons. To address group and time effects in qualitative 
variables, Kruskal-Wallis H, Friedman’s F, or Pearson’s χ2 statistics were used as appropriate. 
 
RESULTS 
Sociodemographic and clinical data 
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Demographic and clinical data of the participants at baseline are summarized in Table 1. No significant differences were 
found between study groups in age, sex, education, clinical variables associated with PD, or the interval between 
assessments. The characteristics of the subjects who remained as study participants and those who dropped 
out are summarized in Supplementary Table 1. 
The longitudinal evolution of clinical variables in all PD patients is summarized in Supplementary Table 2. 
Medication and motor measures showed no significant progression in this follow-up period, and did not differ 
between PD-NC subjects and patients with impaired cognition. MMSE showed significant group differences at 
baseline as well as group and time effects in the longitudinal analysis.  
The progression of the detailed neuropsychological evaluation can be found in Table 2 and Supplementary 
Table 3. Aside from VS/VP measures, significant group-by-time interactions were seen in tests of attention 
and working memory. At follow-up, 17 patients remained as PD-NC (60.71%), 9 remained as PD-MCI (56.25%), 
5 PD-MCI patients reverted to PD-NC (31.25%), 11 PD-NC patients progressed to PD-MCI (39.29%) and 2 PD-
MCI patients fulfilled criteria for PDD (3.1%).  
 
Visuospatial and visuoperceptual performance 
All VS/VP tests showed significant group differences (see Table 2). Significant time and group-by-time 
interaction effects were observed for the SDMT. Post-hoc analyses evidenced that differences were found 
between HC and PD-MCI in all contrasts.  
PCT differed between groups at baseline and follow-up when scored according to the original MMSE criteria 
(χ2=12.800, p=0.002; χ2=8.957, p=0.011 respectively) as well as according to Williams-Gray et al. criteria 
[1,7,8] (χ2=9.295, p=0.010; χ2=8.987, p=0.011 respectively); however, no significant time effects were 
observed for any groups.  
 
MRI evolution  
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Imaging analyses revealed that, compared with PD-NC patients, PD-MCI patients exhibited significantly 
greater progressive cortical thinning in left lateral occipital and inferior parietal regions, and in right medial 
temporal regions (see Figure 1 and Supplementary Table 4). Cortical thinning differences between HC and PD-
NC, and between HC and all PD patients, were not significant.  
Group comparison of global MRI atrophy parameters evidenced that mean thickness differed between groups 
and had a time effect (F(Group)=7.711; p=0.001; F(Time)=9.891, p=0.003; Post-hoc P: PD-MCI vs HC=0.001; 
PD-MCI vs PD-NC=0.016), whereas the increase in the volume of the lateral ventricular system achieved 
statistical significance for time and the interaction between group and time (F(Time): 88.596; p<0.0001; 
F(GroupxTime)=4.745; p=0.012) (see Supplementary Figure 2).  
 
Cortical thickness correlates of visuospatial and visuoperceptual changes 
 Whole-brain imaging analyses showed significant correlations between changes in VS/VP measures and 
cortical thinning over time. In the PD-NC group, FRT also correlated with cortical thinning in the left lateral 
occipital area.  
In PD-MCI patients, changes in PCT scores over time showed a significant cluster in the left entorhinal region 
that involved the middle and inferior temporal gyri, the medial temporal pole, and the parahippocampal, 
fusiform, lingual, and lateral occipital cortices. JLOT was significantly related to cortical atrophy in clusters 
located in the left insula, inferior and superior temporal areas, and the right fusiform gyrus, which extended 
to the left temporal pole, entorhinal, fusiform, and lingual cortices. FRT scores correlated significantly with 
cortical thinning in the left lingual gyrus. SDMT showed significant correlations with reductions in the left 
superior temporal, parahippocampal and lingual, as well as the right parahippocampal cortices (see Figure 2 
and Supplementary Table 5).  
We performed complementary analyses to study the cross-sectional correlates of the tests used in this study 




Figure 3a and 3b and Supplementary Table 6). We analyzed the association between cortical thinning over 
time and the significant longitudinal differences found in neuropsychological measures relative to other 
cognitive domains. In PD-NC patients, the Stroop colors test correlated significantly with left superior parietal 
and frontal regions. In PD-MCI patients, a non-specific widespread pattern of anterior and posterior regions 
correlated bilaterally with TMT-A and Stroop colors tests (see Supplementary Figure 4 and Supplementary 




In the present study, we aimed to investigate the longitudinal differences in cortical thinning between PD 
patients and healthy subjects, as well as the relationship between the progressive loss of VS/VP functions and 
the cortical degeneration underlying these changes in PD patients, grouped according to their cognitive status 
using the Movement Disorder Society Task Force criteria.  
Our results evidence that all the neuropsychological tests with a posterior cortically-based component used in 
this work are sensitive to detect VS/VP impairment in MCI patients. However, among the five VS/VP tests 
used, only the SDMT showed a significant time effect as well as a significant group-by-time interaction, 
indicating that it may be useful for the evaluation of progressive cognitive impairment in PD. Previous 
research in PD cognitive deterioration has also described the progressive decline of visuospatial and 
visuoconstructive functions [1,4,7,8,28,29]. In longitudinal studies, an important issue is the distinction 
between cognitive and motor deficits, as there are several VS/VP tests, such as the clock drawing, the 
pentagon test drawing or the block design, that have a strong motor component. By contrast, in the SDMT, 
the motor component is very low, mainly involving eye tracking. It thus seems to be a suitable test for PD 
follow-up studies. In agreement with our findings, a 3-year multi-center follow-up of a large sample of PD 
patients, using short versions of the JLOT and the SDMT, found statistically significant effects for both tests, 
but the differences were stronger for the SDMT [29].  
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In our previous cross-sectional studies, we demonstrated a relationship between visuospatial and 
visuoperceptual performance and cortical thickness in bilateral temporo-parietal-occipital areas, and 
widespread posterior-anterior white matter microstructure alterations [13,14]. Interestingly, in the present 
study, we have established a relationship between the progressive worsening in VS/VP performance and 
bilateral degeneration of posterior cortical regions. In PD-MCI patients, PCT, JLOT, FRT, and SDMT evidenced 
significant correlates with temporal, occipital, and parietal cortices. In PD-NC we also observed a relationship 
between decreases in FRT scores and the rate of thinning in the occipito-parietal cortex. We highlight the 
emergence of specific neuroanatomical correlates in PD-MCI patients, in absence of a significant time effect in 
neuropsychological performance for most VS/VP tests. This finding reflects that, although performance in 
these tests did not change significantly over time at the group level, there was a variable progressive loss of 
visuospatial and visuoperceptual functions in some PD patients that was explained by the variability in 
thinning of specific posterior cortical brain regions. This notion is supported by the finding that PD-MCI 
patients exhibited extensive progressive reductions in posterior parieto-temporal cortical regions in 
comparison with their cognitively unimpaired PD patient peers, which is in agreement with recent findings 
using the same technique in large study samples [17,18]. 
The neurobiological basis for cognitive dysfunction in PD is unclear, and several factors have been implicated, 
including loss of dopaminergic, noradrenergic, serotonergic, and cholinergic projections to limbic and cortical 
areas, as well as AD-type pathology [30]. Enhanced α-synuclein pathology, together with lysosomal deficits, 
have been linked to poor cognitive evolution in PD patients [31]. Functional cross-sectional studies with 
dopamine tracers and metabolic parameters have established the relevance of posterior regions in cognitive 
decline in PD [32,33], as well as the relationship between visuospatial impairment, posterior cortical regions, 
predominant α-synucleinopathy, and worse cognitive evolution [34,35].  
The strengths of our study are that we applied validated criteria and tests to determine cognitive diagnoses 
[24], established a considerable follow-up interval, used a sensitive technique to identify regional gray matter 
changes associated with PD [36], and used the same MRI scanner, avoiding the variability of multi-center data. 
Our study is limited by the size of the sample due to the considerable attrition, which could in turn affect the 
14 
 
results observed. However, cross-sectional as well as large-scale longitudinal studies of other groups are in 
line with our current findings [11,17,18]. In our study, mean group ages could appear as relatively low 
considering the epidemiological data of PD patents. This might be due to the exclusion of demented PD 
patients, who tend to be older. In fact, the mean age of our sample is similar to those in the abovementioned 
studies that also focused on non-demented PD patients using larger cohorts [17,18].  
In conclusion, the present study establishes the neuroanatomical substrate of the progressive deterioration of 
visuospatial and visuoperceptual performance in PD patients with and without mild cognitive impairment. This 
study reinforces previous findings on the differential progression of atrophy in patients with MCI, thus 
supporting the validity of this construct. These findings give evidence to the notion that the progression of 
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Figure 1. Vertex-wise symmetrized percent change in cortical thickness differences between study groups. 
The scale bar shows P values. PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: 




Figure 2. Vertex-wise symmetrized percent change in cortical thickness correlations with VS/VP measures in 
PD patients. The scale bar shows P values. PD-NC: Parkinson’s disease patients without mild cognitive 
impairment; PD-MCI: Parkinson’s disease patients with mild cognitive impairment; FRT: Facial Recognition 






Table 1. Demographic and clinical data of the participants at baseline. 
 
HC (n=20) PD-NC (n=28) PD-MCI (n=16) F, χ2, t, U 
Interval (years) 3.90 ± 0.32 3.89 ± 0.41 3.94 ± 0.59 0.065a 
Age 65.50 ± 8.00 59.50 ± 9.58 64.63 ± 9.67 3.010a 
Sex (male/female) 10/10 20/8 10/6 2.286b 
Education 11.10 ± 4.13 12.96 ± 4.87 11.25 ± 5.94 1.045a 
MMSE 29.75 ± 0.44 29.54 ± 0.69 28.69 ± 1.54 6.481a* 
Evolution (years)  6.50 ± 3.87 8.03 ± 6.73 -0.814c 
Age at onset  53.00 ± 10.21 56.91 ± 12.22 -1.136c 
LEDD  700.79 ± 470.61 675.63 ± 535.21 0.162c 
UPDRS-III  13.93 ± 9.19 11.75 ± 11.01 185.000d 










HC: Healthy controls; PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: 
Parkinson’s disease patients with mild cognitive impairment; MMSE: Mini-Mental State Examination; LEDD: 
Levodopa Equivalent Daily Dose; UPDRS-III: Unified Parkinson’s disease Rating Scale; H&Y: Hoehn and Yahr 
scale. Values are presented as mean ± standard deviation. a: F ANOVA statistics; b: Pearson’s χ2 statistics; c: 
Student t test statistics; d: Mann-Whitney U statistics. *significant at p<0.01.  
 
Table 2. Group comparison of VS/VP performance between healthy subjects, PD patients without MCI, and PD 
patients with MCI. 
 HC PD-NC PD-MCI 























































































































HC: Healthy controls; PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: 
Parkinson’s disease patients with mild cognitive impairment. PCT: Pentagon Copying Test; JLOT: Judgment of 
Line Orientation Test; VFDT: Visual Form Discrimination Test; FRT: Facial Recognition Test; SDMT: Symbol Digit 





Supplementary Figure 1. Flowchart summarizing sample evolution from screening phase to follow-up. PD: 





Supplementary Figure 2. a) Mean Thickness (mm2) and b) LVS (cm3) estimated marginal means at baseline and 
follow-up in study groups. HC: Healthy controls; PD-NC: Parkinson’s disease patients without mild cognitive 







Supplementary Figure 3a. Vertex-wise cortical thickness one-tail correlations with VS/VP measures in PD 
patients at baseline. The scale bar shows P values. PD-NC: Parkinson’s disease patients without mild cognitive 
impairment; PD-MCI: Parkinson’s disease patients with mild cognitive impairment; JLOT: Judgment of Line 







Supplementary Figure 3b. Vertex-wise cortical thickness one-tail correlations with VS/VP measures in PD 
patients at follow-up. The scale bar shows P values. PD-NC: Parkinson’s disease patients without mild 
cognitive impairment; PD-MCI: Parkinson’s disease patients with mild cognitive impairment; PCT: Pentagon 
Copying Test; JLOT: Judgment of Line Orientation Test; FRT: Facial Recognition Test; SDMT: Symbol Digit 
Modalities Test.  
 
 
Supplementary Figure 4. Vertex-wise symmetrized percent change in cortical thickness one-tail correlations 
with neuropsychological measures in PD patients. The scale bar shows P values; warmth scale represents 
positive correlations; cold scale represents negative correlations. PD-NC: Parkinson’s disease patients without 
mild cognitive impairment; PD-MCI: Parkinson’s disease patients with mild cognitive impairment; TMT-A: Trail 






Supplementary Table 1. Sociodemographic and clinical data of PD subjects that participated in the study and 
those who dropped out after baseline assessment 
 
Study PD participants (n=44) Dropped out (n=48) T, χ2, U 
Age 61.68 ± 9.93 66.08 ± 11.79 -1.927 (p=0.057)a 
Sex (male/female) 30/14 25/23 2.474 (p=0.116)b 
Education 12.07 ± 5.58 9.27 ± 4.84 2.575 (p=0.012)a 
LEDD 716.33 ± 495.85 889.09 ± 482.90 -1.646 (p=0.103)a 
UPDRS-III 14.41 ± 9.40 20.44 ± 11.52 386.000 (p=0.019)c 
H&Y 1.60 ± 0.65 2.00 ± 0.65 421.000 (p=0.016)c 
Age at onset 54.71 ± 10.88 57.28 ± 13.30 -0.995 (p=0.322)a 
Evolution 7.33 ± 5.34 9.35 ± 6.28 -1.658 (p=0.101)a 
MMSE 29.16 ± 1.24 28.96 ± 0.99 0.863 (p=0.390)a 
MCI 13 11 0.778 (p=0.438)b 
Hallucinations 7 12 1.158 (p=0.282)b 
BDI 8.33 ± 5.39 13.43 ± 5.87  -4.051 (p<0.001)a 
AES 11.68 ± 7.06 14.66 ± 7.85 -1.805 (p=0.075)a 
JLOT 22.75 ± 4.77 20.57 ± 4.85 2.156 (p=0.034)a 
VFDT 28.66 ± 2.92 27.02 ± 3.83 2.293 (p=0.024)a 
FRT 21.32 ± 3.06 21.00 ± 2.44 0.551 (p=0.583)a 
PCT 3MS 9.52 ± 0.88 9.09 ± 1.30 1.871 (p=0.065)a 
PCT Original (incorrect) 5 10 1.622 (p=0.203)b 
Attention and working memory 0.18 ± 0.61 0.47 ± 0.78 -1.790 (p=0.078)a 
Executive functions -0.24 ± 1.10 -0.71 ± 0.99 2.107 (p=0.038)a 
Memory -0.46 ± 1.36 -1.16 ± 1.44 2.347 (p=0.021)a 
Language 0.05 ± 0.90 -0.51 ± 1.21 2.474 (p=0.015)a 
Visuospatial and visuoperceptual -0.37 ± 0.94 -0.88 ± 1.06 2.368 (p=0.020)a 
PD: Parkinson’s disease patients; LEDD: Levodopa Equivalent Daily Dose; UPDRS-III: Unified Parkinson’s disease Rating Scale; H&Y: 
Hoehn & Yahr; MMSE: Mini-Mental State Examination; MCI: Mild Cognitive Impairment; BDI: Beck Depression Inventory: AES: 
Apathy Evaluation Scale; JLOT: Judgment of Line Orientation test; VFDT: Visual Form Discrimination test; FRT: Facial Recognition Test; 
PCT: Pentagon Copying Test; 3MS: Modified Mini-Mental State. Values are presented as mean ± standard deviation. a: Student t test 
statistics; b: Pearson’s χ2 statistics; c: Mann-Whitney U statistics.  
 
Supplementary Table 2. Progression of clinical variables in PD participants 
 Baseline Follow-up F 
(Group) F (Time) 
F (Group 
by time) HC PD-NC PD-MCI HC PD-NC PD-MCI 












6.421* 11.116* 1.289 




 720.48 ±  693.28 ± 
481.07  
0.044 0.068 0.989 




































HC: Healthy controls; PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: Parkinson’s disease patients 
with mild cognitive impairment; GxT: Group by time interaction; MMSE: Mini-Mental State Examination; LEDD: Levodopa Equivalent 
Daily Dose, UPDRS-III: Unified Parkinson’s disease Rating Scale; H&Y: Hoehn & Yahr. *Significant at p<0.01.  
Supplementary Table 3. Group comparison of neuropsychological performance between healthy subjects, 
PD patients without MCI, and PD patients with MCI 
 HC PD-NC PD-MCI 












































































































































































































































HC: Healthy controls, PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: Parkinson’s disease patients 
with mild cognitive impairment; TMT: Trail Making Test; DS: Digit Span; Stroop W-C: Stroop Words-Colors test; BNT: Boston Naming 
Test; RAVLT: Rey Auditory Verbal Learning Test. Values are presented as mean ± standard deviation. a: Significant post-hoc contrasts 
between HC and PD-MCI at p<0.01. b: Significant post-hoc contrasts between PD-NC and PD-MCI at p<0.05.  
 
Supplementary Table 4. Significant clusters showing cortical thickness differences over time between PD 
patients without MCI and PD patients with MCI 





Talairach coordinates  
of the maxima Z value 
Clusterwise  
probability 
X Y Z 
PD-NC vs PD-MCI 
Left lateral occipital 2505.31 -41.9 -78.3 -2.8 3.440 0.00010 
Left inferior parietal 2013.90 -40.7 -64.8 30.6 2.333 0.00030 
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Supplementary Table 5. Significant clusters showing cortical thickness correlations over time with VS/VP 
measures in PD patients without MCI and PD patients with MCI 
 





Talairach coordinates  
of the maxima Z value 
Clusterwise  
probability 
X Y Z 
PD-NC FRT 
Left lateral occipital 3027.57 -19.9 -94.5 8.0 3.766 0.00010 
PD-MCI PCT 
Left entorhinal 3430.28 -32.1 -16.9 -24.3 4.734 0.00010 
JLOT 
Left insula 1873.12 -37.5 -19.2 20.0 5.084 0.00020 
Left inferior temporal 1927.49 -37.7 1.7 -31.5 4.705 0.00020 
Left fusiform 1053.63 -29.5 -69.5 -5.6 4.571 0.01660 
Left superior temporal 1475.99 -56.0 -13.6 -5.1 3.490 0.00160 
Right fusiform 1475.55 35.1 -43.2 -9.6 4.136 0.00180 
FRT 
Left lingual 1054.57 -13.1 -56.8 2.5 3.264 0.02880 
SDMT 
Left superior temporal 2779.89 -53.5 -13.6 -6.6 4.351 0.00010 
Left parahippocampal 1182.41 -31.7 -24.3 -18.5 3.920 0.00770 
Left lingual 1311.56 -14.0 -85.3 -4.2 3.761 0.00360 
Right parahippocampal 1651.06 31.9 -22.5 -20.4 4.158 0.00070 
PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: Parkinson’s disease patients with mild cognitive 
impairment; FRT: Facial Recognition Test; PCT: Pentagon Copying Test; JLOT: Judgment of Line Orientation test; SDMT: Symbol Digit 





Supplementary Table 6. Significant clusters showing cross-sectional cortical thickness correlations with 
VS/VP measures in PD patients without MCI and PD patients with MCI at baseline and follow-up assessments 
 





Talairach coordinates  
of the maxima Z value 
Clusterwise  
probability 





Right superior parietal 2602.51 19.5 -60.4 42.7 2.804 0.01350 
SDMT 
Left fusiform 2026.16 -38.8 -62.4 -3.5 2.189 0.05090 
Right fusfirom 6744.71 40-4 .50.3 -10.0 3.032 0.00020 
PD-MCI PCT 
Left precentral 1528.65 -23.8 -20.9 51.2 4.799 0.01690 
Right superior temporal 2004.66 65-2 -20.3 4.3 2.668 0.03130 
JLOT 
Left superior temporal 2324.53 -48.7 -17.4 -9.9 3.793 0.00760 
Left precentral 2039.85 -23.6 -26.2 48.9 4.422 0.01840 
Left fusiform 1764.37 -26.1 -79.1 -3.8 3.439 0.04110 
Right precentral 5038.47 27.6 -25.0 46.2 3.819 0.00020 
Right precuneus 2017.40 11.9 -51.5 14.2 3.876 0.03000 
Right superior temporal 1936.40 46.6 -25.3 -1.2 5.428 0.03780 
FRT 
Left middle temporal 3327.92 -62.3 -18.1 -13.4 4.158 0.00020 
SDMT 
Left precentral 3347.49 -22.7 -23.5 48.7 4.047 0.00020 
Left inferior parietal 2978.70 -48.0 -61.4 10.4 3.777 0.00070 
Left isthmus cingulate 2458.70 -9.1 -54.0 11.4 4.488 0.00430 
Left fusiform 1890.21 -27.0 -77.2 -2.3 2.682 0.02840 
Right superior temporal 5620.20 57.0 -17.0 -1.2 3.927 0.00020 





Left superior temporal 2765.13 -42.7 -3.0 -18.3 2.856 0.01320 
JLOT 
Right lateral occipital 2510.83 18.7 -95.5 -6.3 2.649 0.02230 
FRT 
Left precuneus 3939.25 -20.8 -60.9 12.3 3.947 0.00050 
Right cuneus 7475.92 8.7 -82.4 24.4 2.948 0.00020 
SDMT 
Left precuneus 4138.70 -21.3 -60.7 17.5 3.381 0.00020 
PD-MCI PCT 
Left middle temporal 3196.58 -51.3 -26.0 -9.4 5.016 0.00150 
Left parahippocampal 3141.48 -22.4 -38.6 -8.0 3.072 0.00200 
JLOT 
Left bankssts 6566.60 -48.9 -39.5 5.5 3.308 0.00020 
Left fusiform 2971.92 -31.6 -42.9 -11.9 3.020 0.00310 
Left precuneus 2309.59 -9.1 -56.5 18.0 2.939 0.01960 
Right superior temporal 5655.28 46.2 4.2 -18.6 3.430 0.00020 
Right parahippocampal 5118.58 24.3 -41.3 -5.1 4.188 0.00020 
Right caudal middle 
frontal 
3236.30 39.8 2.7 34.9 4.450 0.00300 
FRT 
Left middle temporal 1989.50 -48.1 -3.4 -27.5 2.832 0.04150 
SDMT 
Left inferior parietal 7774.24 -50.1 -61.2 12.5 3.701 0.00020 
Left fusiform 3399.89 -40.3 -54.6 -4.8 3.234 0.00100 
Left precuneus 2266.55 -23.6 -56.2 8.9 3.355 0.02190 
Right superior temporal 6331.24 46.3 1.7 -17.8 4.620 0.00020 
PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: Parkinson’s disease patients with mild cognitive 







Supplementary Table 7. Significant clusters showing cortical thickness correlations over time with 
neuropsychological measures in PD patients without MCI and PD patients with MCI 
 





Talairach coordinates  
of the maxima Z value 
Clusterwise  
probability 
X Y Z 
PD-NC Stroop colors test 
Left superior frontal 1397.49 -9.0 30.6 48.6 3.390 0.04230 
Left superior parietal 1380.02 -17.7 -76.4 34.6 2.253 0.04450 
PD-MCI TMT-A 
Left parahippocampal 23479.36 -32.0 -25.0 -17.3 -5.626 <0.00001 
Left lateral occipital 2288.44 -39.1 -83.7 2.8 -4.640 0.00070 
Left inferior parietal 2092.69 -31.3 -68.0 40.0 -2.677 0.00050 
Right superior temporal 4174.33 51.2 6.8 -13.3 -4.111 0.00020 
Right superior frontal 3023.02 13.3 15.6 34.1 -4.092 0.00020 
Right lateral occipital 2021.06 41.0 -69.1 4.6 -4.244 0.00200 
Right lingual 1851.08 28.1 -49.3 -2.0 -3.457 0.00480 
Stroop colors test 
Left supramarginal 14221.99 -57.0 -25.0 18.5 6.435 0.00020 
Left pericalcarine 4167.83 -16.4 -73.9 12.8 3.409 0.00020 
Left inferior parietal 1744.34 -42.3 -67.2 24.2 3.487 0.00660 
Left lateral occipital 1267.06 -33.5 -85.4 -0.6 3.655 0.04410 
Right paracentral 5438.37 16.0 -20.6 36.8 5.442 0.00020 
Right parahippocampal 2506.54 32.8 -22.8 -19.1 4.769 0.00020 
Right lateral occipital 2373.49 39.8 -67.2 3.4 3.294 0.00040 
PD-NC: Parkinson’s disease patients without mild cognitive impairment; PD-MCI: Parkinson’s disease patients with mild cognitive 
impairment; TMT-A: Trail Making Test part A.  
 
 
 
